{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Daclizumab",
  "nciThesaurus": {
    "casRegistry": "152923-56-3",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.",
    "fdaUniiCode": "CUJ2MVI71Y",
    "identifier": "C1569",
    "preferredName": "Daclizumab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C20401",
      "C574"
    ],
    "synonyms": [
      "Anti-Tac",
      "Anti-Tac Humanized Monoclonal Antibody",
      "Anti-Tac Monoclonal Antibody",
      "DACLIZUMAB",
      "Dacliximab",
      "Daclizumab",
      "Humanized Anti-Tac Monoclonal Antibody",
      "Monoclonal Antibody Anti-Tac",
      "Zenapax",
      "daclizumab"
    ]
  }
}